Summit Therapeutics PLC (NASDAQ: SMMT) is one of 292 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Summit Therapeutics PLC to similar companies based on the strength of its institutional ownership, profitability, risk, analyst recommendations, dividends, valuation and earnings.

Valuation and Earnings

This table compares Summit Therapeutics PLC and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Summit Therapeutics PLC $30.33 million -$9.46 million -35.40
Summit Therapeutics PLC Competitors $258.58 million $65.85 million -7.26

Summit Therapeutics PLC’s peers have higher revenue and earnings than Summit Therapeutics PLC. Summit Therapeutics PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Summit Therapeutics PLC has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Summit Therapeutics PLC’s peers have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.

Institutional & Insider Ownership

21.8% of Summit Therapeutics PLC shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Summit Therapeutics PLC and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Summit Therapeutics PLC -12.44% -29,334.40% -7.61%
Summit Therapeutics PLC Competitors -5,801.68% -451.23% -42.41%

Analyst Ratings

This is a breakdown of current ratings and price targets for Summit Therapeutics PLC and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics PLC 0 0 3 0 3.00
Summit Therapeutics PLC Competitors 741 2975 11076 223 2.72

Summit Therapeutics PLC presently has a consensus price target of $27.00, suggesting a potential upside of 117.92%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 31.76%. Given Summit Therapeutics PLC’s stronger consensus rating and higher probable upside, equities analysts clearly believe Summit Therapeutics PLC is more favorable than its peers.

Summary

Summit Therapeutics PLC peers beat Summit Therapeutics PLC on 7 of the 12 factors compared.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.